Innovating Works

filtrando por convocatoria: HORIZON-HLTH-2022-TOOL-11-01

More-EUROPA: More Effectively Using Registries to suppOrt PAtient-centered Regulatory and HTA decision-making ACADEMISCH ZIEKENHUIS GRONINGEN tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 While randomized controlled trials (RCTs) remain the mainstay in drug development, approval, and reimbursement, the potential of real world...
2022-11-24 - 2027-12-31 | Financiado
METHYLOMIC: DNA methylation markers to predict treatment success of biologicals in Crohn’s disease. Academisch Medisch Centrum AMC tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid...
2022-11-24 - 2026-12-31 | Financiado
Hypermarker: Personalised pharmacometabolomic optimisation of treatment for hypertension UNIVERSITAIR MEDISCH CENTRUM UTRECHT tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Hypertension, or high blood pressure (BP), is a serious medical condition, and the single biggest contributor to circulatory diseases which...
2023-01-01 - 2026-12-31 | Financiado
ONCOVALUE: Implementing value-based oncology care at European cancer hospitals: An AI-based framework for asses... HUSYHTYMA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 ONCOVALUE will unlock the full potential of real world data (RWD) collected in European cancer hospitals and institutes to ease the decision...
2022-12-01 - 2026-11-30 | Financiado
Real4Reg: Development, optimisation and implementation of artificial intelligence methods for real world data... BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Real-world evidence derived from real-world data (RWD) has a promising role to inform regulatory decision-making. Based on highly relevant u...
2023-01-01 - 2026-12-31 | Financiado
SQUEEZE: Maximising Impact of Prescription Drugs in Rheumatoid Arthritis MEDIZINISCHE UNIVERSITAET WIEN tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 The SQUEEZE consortium comprehensively addressed how biomarkers can be used to optimize disease modifying antirheumatic drugs (DMARDs) for r...
2022-12-01 - 2027-11-30 | Financiado
BIOTOOL-CHF: BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart fai... IRCCS AZIENDA OSPEDALIERO UNIVERSITARIA DI BOLOGNA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Heart failure (HF) is a chronic clinical condition involving up to 6.5 million people in Europe, the most frequent cause of hospitalization...
2023-10-01 - 2028-09-30 | Financiado
PRIME-CKD: Personalized Drug Response: IMplementation and Evaluation in CKD ACADEMISCH ZIEKENHUIS GRONINGEN tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapi...
2023-01-01 - 2027-12-31 | Financiado
PoCCardio: Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk... MEDIZINISCHE UNIVERSITAT GRAZ tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Besides established risk factors such as elevated blood pressure, b...
2023-12-01 - 2028-11-30 | Financiado
REDDIE: Real-world evidence for decisions in diabetes MEDIZINISCHE UNIVERSITAT GRAZ tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 Randomised controlled trials are the cornerstone of evidence-based medicine. However, the digitisation of real-world data (RWD) including da...
2023-01-01 - 2026-12-31 | Financiado
OPADE: Optimise and predict antidepressant efficacy for patient with major depressive disorders using multi... FONDAZIONE EBRIS tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depre280M of...
2022-12-01 - 2027-05-31 | Financiado
HT-ADVANCE: Improving treatment efficacy in hypertension by biomarker-guided personalised decision support INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 In HT-ADVANCE we aim to revolutionise personalised management of arterial hypertension (HT) by using multi-omics (MOMICS) stratification bio...
2023-03-01 - 2029-02-28 | Financiado
INSAFEDARE: INNOVATIVE APPLICATIONS OF ASSESSMENT AND ASSURANCE OF DATA AND SYNTHETIC DATA FOR REGULATORY DECISI... COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 INSAFEDARE aims to provide a toolkit to enable cost-effective and high assurance decision-making in the context of the processes that all st...
2023-11-01 - 2026-10-31 | Financiado
REALM: Real-world-data Enabled Assessment for heaLth regulatory decision-Making UNIVERSITEIT MAASTRICHT tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 The overall aim of the REALM project is to create a collaborative framework for regulatory authorities, application developers, healthcare p...
2023-01-01 - 2026-12-31 | Financiado